Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Excaliard Pharmaceuticals, a late stage preclinical company developing targeted therapeutics for the treatment of dermatological disorders and fibrotic diseases, has appointed Lincoln Krochmal as president and CEO and Jeff Jensen as head of clinical operations.
Subscribe to our email newsletter
Dr Krochmal has over 25 years experience in the pharmaceutical and consumer goods industries. Prior to joining Excaliard in September 2008, Dr Krochmal served as executive vice president of research and product development for Connetics, a specialty dermatology company headquartered in Palo Alto, California, until the company’s acquisition by Stiefel Laboratories.
Mr Jensen brings to Excaliard over 25 years of clinical operations experience and has overseen the outsourcing of hundreds of clinical trials. Prior to joining Excaliard, he was senior director of clinical operations at Metabasis Therapeutics and a director of study management and development operations at Pfizer.
Gordon Foulkes, Excaliard’s acting CEO and a managing director at RiverVest Venture Partners, said: “The board could not be more enthusiastic than with the appointment of Dr Krochmal to lead the company going forward. His track record in drug approvals in this area is truly outstanding. We are also extremely pleased to have Jeff Jensen join Excaliard as head of clinical operations as he brings a wealth of invaluable experience in clinical trials operations.”